Analysis of Nausea in Clinical Studies of Lubiprostone for the Treatment of Constipation Disorders

Digestive Diseases and Sciences

Volumn 62, Issue 12, 2017, Pages 3568-3578

  Cryer, Byron ^a   Drossman, Douglas A ^b   Chey, William D ^c   Webster, Lynn ^d   Habibi, Sepideh ^e   Wang, Martin ^e  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d PRA HEALTH SCIENCES   (United States)

^e Sucampo Pharma Americas   (United States)

Author keywords

Chronic idiopathic constipation; Irritable bowel syndrome with constipation; Lubiprostone; Nausea; Opioid induced constipation

Indexed keywords

LUBIPROSTONE; PLACEBO; CHLORIDE CHANNEL STIMULATING AGENT;

AGED; ARTICLE; BODY MASS; CONSTIPATION; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NAUSEA; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT INTERRUPTION; CHEMICALLY INDUCED; META ANALYSIS;

CHLORIDE CHANNEL AGONISTS; CONSTIPATION; HUMANS; LUBIPROSTONE; NAUSEA;

EID: 85028522333     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-017-4680-1     Document Type: Article

References (34)

1. Amitiza (lubiprostone) [package insert]. Deerfield, IL: Takeda Pharmaceuticals; 2016.
2. Lacy B, Levy L. Lubiprostone: a chloride channel activator. J Clin Gastroenterol. 2007;41:345–351.
3. Camilleri M, Bharucha A, Ueno R, et al. Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. Am J Physiol Gastrointest Liver Physiol. 2006;290:G942–G947.
4. Fukudo S, Hongo M, Kaneko H, Takano M, Ueno R. Lubiprostone increases spontaneous bowel movement frequency and quality of life in patients with chronic idiopathic constipation. Clin Gastroenterol Hepatol. 2015;13:294.e295–301.e295.
5. Johanson J, Ueno R. Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety. Aliment Pharmacol Ther. 2007;25:1351–1361.
6. Lembo A, Johanson J, Parkman H, Rao S, Miner PJ, Ueno R. Long-term safety and effectiveness of lubiprostone, a chloride channel (ClC-2) activator, in patients with chronic idiopathic constipation. Dig Dis Sci. 2011;56:2639–2645.
7. Johanson J, Morton D, Geenen J, Ueno R. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am J Gastroenterol. 2008;103:170–177.
8. Barish C, Drossman D, Johanson J, Ueno R. Efficacy and safety of lubiprostone in patients with chronic constipation. Dig Dis Sci. 2010;55:1090–1097.
9. Johanson JF, Gargano MA, Holland PC, Patchen ML, Ueno R. Phase III patient assessments of the effects of lubiprostone, a chloride channel-2 (ClC-2) activator, for the treatment of constipation. Am J Gastroenterol. 2005;100:S329–S330.
10. Ueno R, Wahle A, Panas R, Joswick TR, Rivera E. Evaluation of safety and efficacy in a twelve-month study of lubiprostone for the treatment of chronic idiopathic constipation. Am J Gastroenterol. 2006;101:S491.
11. Jamal MM, Adams AB, Jansen JP, Webster LR. A randomized, placebo-controlled trial of lubiprostone for opioid-induced constipation in chronic non-cancer pain. Am J Gastroenterol. 2015;110:725–732.
12. Cryer B, Katz S, Vallejo R, Popescu A, Ueno R. A randomized study of lubiprostone for opioid-induced constipation in patients with chronic noncancer pain. Pain Med. 2014;15:1825–1834.
13. Drossman DA, Chey WD, Johanson JF, et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome–results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther. 2009;29:329–341.
14. Johanson JF, Drossman DA, Panas R, Wahle A, Ueno R. Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 2008;27:685–696.
15. Chey W, Drossman D, Johanson J, Scott C, Panas R, Ueno R. Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 2012;35:587–599.
16. Spierings E, Joswick T, Lindner E, Woldegeorgis F, Ueno R. Long-term safety and efficacy of lubiprostone in opioid-induced bowel dysfunction in patients with chronic, non-cancer pain: Results of a phase 3, open-label clinical trial. Paper presented at American College of Gastroenterology Annual Scientific Meeting; October 19–24, 2012; Las Vegas, Nevada.
17. Halpern SH, Douglas MJ. Appendix- Jadad scale for reporting randomized controlled trials. In: Halpern SH, Douglas MJ, eds. Evidence-based Obstetric Anesthesia. Oxford, UK: Blackwell Publishing Ltd; 2005:237–238.
18. Mayo Clinic. Nausea and vomiting causes: symptoms. http://www.mayoclinic.org/symptoms/nausea/basics/causes/sym-20050736. Accessed February 25, 2015.
19. Labianca R, Sarzi-Puttini P, Zuccaro SM, Cherubino P, Vellucci R, Fornasari D. Adverse effects associated with non-opioid and opioid treatment in patients with chronic pain. Clin Drug Investig. 2012;32:53–63.
20. Mareya SM, Wang M, Losch-Beridon T, Lichtlen P. Su1586 lubiprostone responder rates in patients with chronic idiopathic constipation: increased frequency of spontaneous bowel movements and improved constipation-related symptoms. Gastroenterol. 2016;150:S534–S535.
21. Losch-Beridon T, Mareya S, Wang M, Lichtlen P. Su1585 lubiprostone responder rates in patients with opioid-induced constipation: increased frequency of complete spontaneous bowel movements. Gastroenterol. 2016;150:S534.
22. Chang L, Chey W, Drossman D, et al. Mo1262 effects of baseline abdominal pain on response to lubiprostone in patients with constipation-predominant irritable bowel syndrome. Gastroenterol. 2015;148:653.
23. Choung RS, Locke GR 3rd, Schleck CD, Zinsmeister AR, Talley NJ. Cumulative incidence of chronic constipation: a population-based study 1988–2003. Aliment Pharmacol Ther. 2007;26:1521–1528.
24. Kepenekci I, Keskinkilic B, Akinsu F, et al. Prevalence of pelvic floor disorders in the female population and the impact of age, mode of delivery, and parity. Dis Colon Rectum. 2011;54:85–94.
25. Kurniawan I, Simadibrata M. Management of chronic constipation in the elderly. Acta Med Indones. 2011;43:195–205.
26. McCrea GL, Miaskowski C, Stotts NA, Macera L, Varma MG. A review of the literature on gender and age differences in the prevalence and characteristics of constipation in North America. J Pain Symptom Manage. 2009;37:737–745.
27. Pare P, Ferrazzi S, Thompson WG, Irvine EJ, Rance L. An epidemiological survey of constipation in canada: definitions, rates, demographics, and predictors of health care seeking. Am J Gastroenterol. 2001;96:3130–3137.
28. Preston DM, Lennard-Jones JE. Severe chronic constipation of young women: ‘idiopathic slow transit constipation’. Gut. 1986;27:41–48.
29. Gallegos-Orozco JF, Foxx-Orenstein AE, Sterler SM, Stoa JM. Chronic constipation in the elderly. Am J Gastroenterol. 2012;107:18–25.
30. Chamberlain S, Rao S. Safety evaluation of lubiprostone in the treatment of constipation and irritable bowel syndrome. Expert Opin Drug Saf. 2012;11:841–850.
31. Hooks S, Rutland T, Di Palma J. Lubiprostone neither decreases gastric and small-bowel transit time nor improves visualization of small bowel for capsule endoscopy: a double-blind, placebo-controlled study. Gastrointest Endosc. 2009;70:942–946.
32. Song J, Yin J, Xu X, Chen J. Prokinetic effects of large-dose lubiprostone on gastrointestinal transit in dogs and its mechanisms. Am J Transl Res. 2015;7:513–521.
33. Barbera R, Feinle C, Read NW. Abnormal sensitivity to duodenal lipid infusion in patients with functional dyspepsia. Eur J Gastroenterol Hepatol. 1995;7:1051–1057.
34. Tjeerdsma H, Smout A, Akkermans L. Voluntary suppression of defecation delays gastric emptying. Dig Dis Sci. 1993;38:832–836.